Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G10 | O15496 | 2/20 | 0.55 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.47 |
| ▸ | CTSK | P43235 | 2/20 | 0.47 |
| ▸ | CTSL | P07711 | 2/20 | 0.47 |
| ▸ | CTSB | P07858 | 1/20 | 0.47 |
| ▸ | CTSS | P25774 | 1/20 | 0.47 |
| ▸ | AAK1 | Q2M2I8 | 4/20 | 0.46 |
| ▸ | CA1 | P00915 | 1/20 | 0.45 |
| ▸ | CA2 | P00918 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | FOLH1 | Q04609 | 3/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7434716 | 0.91 | PLA2G10 (0.51) | PLA2G10CAPN1CTSKCTSLCTSB | |
| SCHEMBL29846262 | 0.87 | CA1 (0.48) | PLA2G10CAPN1CTSKCTSLCTSB | |
| SCHEMBL7444041 | 0.85 | TDP1 (0.49) | CAPN1CTSKCTSLCTSBCTSS | |
| SCHEMBL28166482 | 0.85 | CTSK (0.44) | PLA2G10CTSKCTSSCA1CA2 | |
| SCHEMBL19227630 | 0.82 | CA1 (0.58) | CAPN1CTSKCTSLCTSBCTSS | |
| SCHEMBL4934738 | 0.81 | CTSS (0.51) | PLA2G10CAPN1CTSKCTSLCTSB | |
| SCHEMBL57148 | 0.81 | CA1 (0.50) | CAPN1CTSKCTSLCTSBCTSS | |
| SCHEMBL9396774 | 0.81 | CA1 (0.46) | CTSKCTSLCTSBCTSSCA1 | |
| SCHEMBL18866617 | 0.81 | CA1 (0.46) | CTSKCTSLCTSBCTSSCA1 | |
| SCHEMBL56754 | 0.81 | CTSS (0.51) | PLA2G10CAPN1CTSKCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9732105-B2 | Targeted nitroxide agents | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-08-15 | — | — | US | disclosed |
| US-9732105-B2 | Targeted nitroxide agents | University of Pittsburgh—of the Commonwealth System of Higher Education (US) | 2017-08-15 | — | — | US | disclosed |
| US-20160068556-A1 | TARGETED NITROXIDE AGENTS | UNIVERSITY OF PITTSBURGH - OF THE COMMONWEALTH SYSTEM OF HIGHER EDUCATION (US) | 2016-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160068556-A1 | TARGETED NITROXIDE AGENTS | NOXO1, NOX1, TPX2 | PLA2G10 4733/4885CAPN1 733/4885CTSK 2657/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.